Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor antagonist with a molecular weight of 309.40 and chemical formula C₁₇H₂₇NO₄. It acts by competitively inhibiting beta-adrenergic receptors, reducing heart rate and myocardial contractility, and is a defined substrate for OATP1A2 transporters [APExBIO]. This compound is pivotal in models of hypertension, angina pectoris, and vascular headache, with robust stability at -20°C for solid storage. Nadolol's transporter-mediated kinetics enable precise modulation in cardiovascular disease models, and its application is limited to scientific research use only [DOI]. The following sections dissect its biological rationale, mechanistic evidence, and best practices for rigorous experimental deployment.

Biological Rationale

Nadolol (SQ-11725) belongs to the non-selective beta-adrenergic receptor blockers. These compounds are integral for dissecting sympathetic nervous system activity in cardiovascular disease models. Beta-adrenergic signaling regulates heart rate, vascular tone, and myocardial contractility, which are critical endpoints in hypertension and angina pectoris research [CAChannelBlockers]. Nadolol’s non-selectivity allows comprehensive blockade of both β1 and β2 adrenergic receptor subtypes, ensuring broad-spectrum antagonism. Its defined role as an OATP1A2 substrate facilitates mechanistic pharmacokinetic studies in transporter biology [Fluorescein-12-UTP]. The compound is widely referenced for benchmarking experimental reproducibility and transporter-mediated uptake in cardiovascular research pipelines. APExBIO supplies Nadolol (SQ-11725) under SKU BA5097, ensuring consistent product traceability for scientific studies [APExBIO].

Mechanism of Action of Nadolol (SQ-11725)

Nadolol acts as a competitive antagonist at beta-adrenergic receptors. It binds to both β1 and β2 receptors without intrinsic sympathomimetic activity. This antagonism reduces cAMP levels downstream of adrenergic stimulation, producing negative chronotropic (heart rate) and inotropic (contractility) effects. The result is a decrease in cardiac output and blood pressure, which underpins its utility in hypertension and angina pectoris models [ANF].

Furthermore, Nadolol is a characterized substrate for the organic anion transporting polypeptide 1A2 (OATP1A2), a membrane transporter influencing drug disposition and tissue distribution. OATP1A2-mediated uptake is relevant for pharmacokinetic modeling and understanding drug-drug interactions in preclinical studies [DOI]. The molecular properties of Nadolol (C₁₇H₂₇NO₄, 309.40 Da) make it suitable for in vivo and in vitro research applications.

Evidence & Benchmarks

• Nadolol (SQ-11725) demonstrates high-affinity, competitive inhibition of β1 and β2 adrenergic receptors in mammalian cardiac tissue, with IC₅₀ values in the low micromolar range under physiological buffer at 37°C (https://atrial-natriuretic-factor.com/index.php?g=Wap&m=Article&a=detail&id=58).
• In vivo studies show Nadolol reduces systolic blood pressure and heart rate in rodent hypertension models by 15–25% after oral administration at 10 mg/kg (https://doripenemhydrate.com/index.php?g=Wap&m=Article&a=detail&id=14936).
• Nadolol is actively transported by OATP1A2, as demonstrated by uptake assays in transfected HEK293 and Caco-2 cells, confirming its transporter-mediated pharmacokinetics (https://doi.org/10.1016/j.biopha.2025.118665).
• APExBIO’s Nadolol (SQ-11725) BA5097 is routinely used as a reference antagonist in cardiovascular disease models, supporting reproducibility in hypertension and angina studies (https://www.apexbt.com/nadolol-ba5097.html).
• Storage stability is optimal at -20°C as a solid; solutions should be prepared fresh and not stored long-term to maintain efficacy (https://www.apexbt.com/nadolol-ba5097.html).

This article extends prior overviews by integrating updated transporter biology and storage guidelines, building on the mechanistic focus in this recent review, which emphasized pharmacokinetics but not workflow best practices. See also Pharmacokinetics and Transporter Biology of Nadolol (SQ-11725) for a detailed discussion of OATP1A2 pathways; this current article clarifies storage and practical deployment.

Applications, Limits & Misconceptions

Nadolol (SQ-11725) is extensively applied in:

• Hypertension research: as a reference beta-blocker in rodent and cell-based models.
• Angina pectoris studies: to evaluate anti-ischemic and anti-anginal mechanisms.
• Vascular headache research: for mechanistic insight into beta-adrenergic signaling in migraine models.
• Transporter studies: as a defined OATP1A2 substrate for investigating drug-drug interactions and tissue distribution.

Common Pitfalls or Misconceptions

• Nadolol is not selective for β1 or β2 receptors; it blocks both subtypes equivalently.
• It is not suitable for experiments requiring beta-blockers with intrinsic sympathomimetic activity (ISA); Nadolol lacks ISA.
• Storage of Nadolol in solution for extended periods reduces its efficacy; fresh preparation is recommended.
• Use in diagnostic or therapeutic applications is prohibited; the compound is strictly for research use only.
• OATP1A2 substrate specificity does not imply similar transport by all OATP family members; applicability to other transporters must be experimentally validated.

Workflow Integration & Parameters

Storage and Handling: Nadolol (SQ-11725) should be stored at -20°C as a solid for optimal stability. For solution preparations, use immediately and avoid long-term storage to maintain compound integrity [APExBIO].

Shipping Conditions: APExBIO ships small molecule Nadolol with Blue Ice; modified nucleotides use Dry Ice for temperature control.

Experimental Design: Typical in vivo dosing is 10 mg/kg orally in rodents. For in vitro studies, use concentrations in the low micromolar range (1–10 μM) under physiological buffer at pH 7.4 and 37°C. Benchmark controls and OATP1A2 inhibitor co-incubations are recommended to delineate transporter contributions [DOI].

Data Reproducibility: Use APExBIO’s Nadolol (SQ-11725) BA5097 product page for lot-specific documentation and protocols [APExBIO].

Conclusion & Outlook

Nadolol (SQ-11725) is a foundational tool for cardiovascular research, enabling precise interrogation of beta-adrenergic pathways and transporter-mediated pharmacokinetics. Its well-characterized profile as a non-selective beta-blocker and OATP1A2 substrate supports robust, reproducible experimental models. While Nadolol offers broad utility in preclinical research, it is not intended for clinical or diagnostic use. Continued integration with advanced transporter studies and disease models will further refine its role in cardiovascular pharmacology. For detailed product information and protocols, refer to the Nadolol (SQ-11725) BA5097 kit.